These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28526448)

  • 1. The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells.
    Grünig D; Felser A; Bouitbir J; Krähenbühl S
    Toxicol In Vitro; 2017 Aug; 42():337-347. PubMed ID: 28526448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects.
    Haasio K; Nissinen E; Sopanen L; Heinonen EH
    J Neural Transm (Vienna); 2002 Nov; 109(11):1391-401. PubMed ID: 12454735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.
    Fischer JJ; Michaelis S; Schrey AK; Graebner OG; Glinski M; Dreger M; Kroll F; Koester H
    Toxicol Sci; 2010 Jan; 113(1):243-53. PubMed ID: 19783845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the Catechol-O-Methyltransferase Inhibitors Tolcapone and Entacapone on Fatty Acid Metabolism in HepaRG Cells.
    Grünig D; Felser A; Duthaler U; Bouitbir J; Krähenbühl S
    Toxicol Sci; 2018 Aug; 164(2):477-488. PubMed ID: 29688484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production.
    Nissinen E; Kaheinen P; Penttilä KE; Kaivola J; Lindén IB
    Eur J Pharmacol; 1997 Dec; 340(2-3):287-94. PubMed ID: 9537825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
    Korlipara LV; Cooper JM; Schapira AH
    Neuropharmacology; 2004 Mar; 46(4):562-9. PubMed ID: 14975680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo.
    Haasio K; Lounatmaa K; Sukura A
    Exp Toxicol Pathol; 2002 Jul; 54(1):9-14. PubMed ID: 12180806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of entacapone and tolcapone on mitochondrial membrane potential.
    Haasio K; Koponen A; Penttilä KE; Nissinen E
    Eur J Pharmacol; 2002 Oct; 453(1):21-6. PubMed ID: 12393055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.
    Haasio K; Sopanen L; Vaalavirta L; Lindén IB; Heinonen EH
    J Neural Transm (Vienna); 2001; 108(1):79-91. PubMed ID: 11261749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
    Forester SC; Lambert JD
    Carcinogenesis; 2014 Feb; 35(2):365-72. PubMed ID: 24148818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury.
    Longo DM; Yang Y; Watkins PB; Howell BA; Siler SQ
    CPT Pharmacometrics Syst Pharmacol; 2016 Jan; 5(1):31-9. PubMed ID: 26844013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases.
    Lv X; Wang XX; Hou J; Fang ZZ; Wu JJ; Cao YF; Liu SW; Ge GB; Yang L
    Toxicol Appl Pharmacol; 2016 Jun; 301():42-9. PubMed ID: 27089846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
    Kaakkola S; Gordin A; Männistö PT
    Gen Pharmacol; 1994 Sep; 25(5):813-24. PubMed ID: 7835624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
    Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue and interspecies comparison of catechol-
    Jalkanen A; Lassheikki V; Torsti T; Gharib E; Lehtonen M; Juvonen RO
    Xenobiotica; 2021 Mar; 51(3):268-278. PubMed ID: 33289420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
    Forsberg M; Lehtonen M; Heikkinen M; Savolainen J; Järvinen T; Männistö PT
    J Pharmacol Exp Ther; 2003 Feb; 304(2):498-506. PubMed ID: 12538800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.
    Forsberg MM; Huotari M; Savolainen J; Männistö PT
    Eur J Pharm Sci; 2005 Apr; 24(5):503-11. PubMed ID: 15784340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.
    Gerlach M; Ukai W; Ozawa H; Riederer P
    J Neural Transm (Vienna); 2002 May; 109(5-6):789-95. PubMed ID: 12111468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].
    Arnold G; Kupsch A
    Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone.
    De Santi C; Giulianotti PC; Pietrabissa A; Mosca F; Pacifici GM
    Eur J Clin Pharmacol; 1998 May; 54(3):215-9. PubMed ID: 9681662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.